Pro Medicus (ASX:PME) ROCE %: 46.46% (As of Dec. 2025)


ASX:PME Pro Medicus Ltd ASX:PME
98 GF Score
Price A$178.99
GF Value A$244.83
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Pro Medicus ROCE %?

Pro Medicus ASX:PME +3.50% 98 ROCE % is 46.46% as of Dec. 2025. GuruFocus rates ASX:PME with a GF Score™ of 98/100 and a GF Value™ of A$244.83 (Modestly Undervalued). The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Pro Medicus's annualized ROCE % for the quarter that ended in Dec. 2025 was 46.46%.

Pro Medicus  (ASX:PME) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Pro Medicus ROCE % Related Terms

Pro Medicus ROCE % Historical Data

* Premium members only.

The historical data trend for Pro Medicus's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pro Medicus ROCE % Chart

Pro Medicus Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 41.32 52.34 55.57 56.84 60.74

Pro Medicus Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 54.04 61.14 57.81 63.14 46.46
ASX:PME
98GF Score
Pro Medicus Ltd ASX:PME
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pro Medicus ROCE % Calculation

Pro Medicus's annualized ROCE % for the fiscal year that ended in Jun. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=157.614/( ( (257.961 - 34.557) + (338.704 - 43.138) )/ 2 )
=157.614/( (223.404+295.566)/ 2 )
=157.614/259.485
=60.74 %

Pro Medicus's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=181.256/( ( (338.704 - 43.138) + (533.913 - 49.187) )/ 2 )
=181.256/( ( 295.566 + 484.726 )/ 2 )
=181.256/390.146
=46.46 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 46.46% mean?
Pro Medicus (ASX:PME) has a ROCE % of 46.46% as of Dec. 2025.
Is Pro Medicus' ROCE % too high?
Pro Medicus' current ROCE % is 46.46%. The Healthcare Providers & Services industry median ROCE % is 6.41. Pro Medicus' value of 46.46% is 624.8% above this industry median. Overall, Pro Medicus has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pro Medicus' ROCE % compare to VEEV and BTSG?
Pro Medicus' ROCE % of 46.46% can be compared against companies in the Healthcare Providers & Services industry. The industry median ROCE % is 6.41. Pro Medicus' value of 46.46% is 624.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Healthcare Providers & Services company?
The median ROCE % among Healthcare Providers & Services companies is 6.41, based on 648 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pro Medicus's current ROCE % of 46.46% is 624.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median ROCE % is 6.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pro Medicus's current ROCE % is 46.46%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pro Medicus stock overvalued right now?
Based on GuruFocus' analysis, Pro Medicus (ASX:PME) is currently considered Modestly Undervalued. The stock's GF Value™ is A$244.83, compared to a current price of A$178.99 — trading 26.9% below its estimated fair value. The current ROCE % is 46.46% and 624.8% above the Healthcare Providers & Services industry median of 6.41. Pro Medicus' overall GF Score™ is 98/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Pro Medicus (ASX:PME), the current ROCE % is 46.46% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pro Medicus (ASX:PME) Overvalued in 2026?

Based on GuruFocus' analysis, Pro Medicus stock appears to be undervalued. The current stock price of A$178.99 is trading 26.9% below its estimated GF Value™ of A$244.83. GuruFocus considers Pro Medicus to be Modestly Undervalued.

Key valuation signals for ASX:PME:

  • ROCE %: 46.46%
  • GF Value™: A$244.83 vs. price of A$178.99 (26.9% below fair value)
  • GF Score™: 98/100 with 1 warning sign
  • Industry Position: 624.8% above the Healthcare Providers & Services median

No single metric tells the full story. See the ASX:PME stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pro Medicus Business Description

Address 450 Swan Street, Richmond, VIC, AUS, 3121
Pro Medicus is a healthcare IT company specializing in radiology imaging software. Its main product, Visage 7, is a clinical desktop application that radiologists use to view, enhance, and manipulate images from any device and make a diagnosis. Its main customers are US private academic hospitals. In fiscal 2025, Pro Medicus earned 90% of revenue in North America, 8% from Australia, and the remaining 2% in Europe.
98GF Score

Get the complete analysis for ASX:PME

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$178.99
Price
A$244.83
GF Value